THANARA: A Microbiome-Based Skincare Innovation Featuring 4P-Biotics Technology by AL-DNA
Healthy, moisturized, radiant, and youthful skin is a goal for many. Achieving this not only involves "beauty from the inside out" through proper nutrition, hydration, rest, emotional well-being, and balanced exercise, but also relies on effective external skin care--where "good microorganisms" play a significant role.
"Microbiomes are microorganisms that live in our bodies and on our skin. They help maintain skin balance, support overall skin health (such as pH levels, moisture, and skin barrier function), and help prevent infections," explained Associate Professor Dr. Naraporn Somboonna. She emphasized the growing importance of microbiomes in the health and beauty industry.
"Balancing the microbiome is key to restoring healthy skin," Assoc. Prof. Dr. Naraporn shared, introducing the idea behind the innovative skincare formula under the "THANARA" brand, developed by "AL-DNA," a startup incubated by CU Innovation Hub/CU Enterprise.
Inspiration Behind the Skincare Innovation
With her expertise in microbiology and portable genetic testing, Assoc. Prof. Dr. Naraporn has created impactful innovations in various fields. In public health, she developed a three-gene COVID-19 test kit used during the pandemic. In agriculture, she designed an ASFV (African Swine Fever Virus) test kit to help farmers detect infections quickly and conveniently.
In the food industry, she introduced a Live Total Bacteria and Coliform Detections test kit to identify harmful bacteria in food and beverage production. Her interest in microbiomes extends to their roles in human and environmental health. She is also a member of the Multi-Omics for Functional Products in Food, Cosmetics, and Animals Research Unit and the Omics Sciences and Bioinformatics Center at Chulalongkorn University.
Healthy Skin Through Microbiome and 4P-Biotics Technology
According to Assoc. Prof. Dr. Naraporn, AL-DNA has launched two skincare products, both patented and FDA-certified to ensure user safety:
"What makes THANARA unique is its use of 4P-Biotics technology--Probiotics, Parabiotics, Prebiotics, and Postbiotics—to help balance the skin's microbiome," Assoc. Prof. Dr. Naraporn explained. "Moreover, THANARA products are free from potential irritants like alcohol, parabens, and silicone."
AL-DNA: The Future of Health and Beauty
THANARA products are currently available at the Faculty of Science (Research Division), CU Enterprise, and via online channels. Looking ahead, Assoc. Prof. Dr. Naraporn says that AL-DNA plans to expand its line with additional microbiome-based skincare products, including personalized skin analysis and anti-aging treatments.
For more information, please contact Assoc. Prof. Dr. Naraporn Somboonna at the Department of Microbiology, Faculty of Science, Chulalongkorn University, or reach out through CU Enterprise and CU Sci Products and Services, or call +6680-440-4509.
View the photo album of this article at https://www.chula.ac.th/en/highlight/232515/
About Chulalongkorn University
"Chulalongkorn University proudly retains its No. 1 position among Thai universities and ranks 132nd in Asia out of more than 2,000 institutions in the THE Asia University Rankings 2025—a testament to the excellence of Thai higher education on the regional stage."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
a day ago
- Korea Herald
Korea urges measles vaccination before overseas travel as imported cases rise
Amid a sharp rise in imported cases of measles recently, the Korea Disease Control and Prevention Agency has urged travelers to ensure they are fully vaccinated against the infectious disease before going abroad. According to KDCA data released Wednesday, 68 cases of measles had been confirmed in Korea as of Aug. 9, since the government began to closely observe outbreak cases in December 2024. The number of cases observed most recently was a 1.4-fold increase from the number of cases recorded over the same period a year prior. Of the total number of cases, 49 — 72.1 percent — were infections contracted overseas and detected after entry. A majority of the cases, adding up to 42 in total, were found to be contracted from Vietnam, followed by South Africa, Uzbekistan, Thailand, Italy and Mongolia. The nineteen other domestic cases were also linked to these imported infections, with transmission occurring in households and medical facilities with measles patients. Adults made up a majority of the cases, with 77.9 percent of patients aged 19 or older. Notably, 54.4 percent were either unvaccinated against measles or were unsure of their vaccination status. Citing data from the World Health Organization, the KDCA said some 360,000 measles cases were reported globally in 2024, with outbreaks still continuing to be observed into this year in Europe, the Middle East, Africa and Southeast Asia — regions all frequented by Korean travelers. According to the agency, lower vaccination rates for measles worldwide have fueled the resurgence. Due to the COVID-19 pandemic, measles vaccinations were disrupted due to a strain in the health care system as well as lockdowns that made it difficult for some families to access vaccination services. In 2023, the global rate of the second-dose measles vaccination — which is crucial for full immunity — was 74 percent, below the WHO-recommended 95 percent. To stay safe from measles infections, the KDCA has advised travelers to measles-affected countries to complete the two-dose measles, mumps and rubella vaccine. Those developing a fever or a rash within three weeks of returning to South Korea from a measles-affected country should wear a mask, minimize contact with others and inform medical authorities of recent travel before seeking care. Extra caution is urged for households with infants too young for vaccination, pregnant women and those with weakened immune systems.
Korea Herald
2 days ago
- Korea Herald
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar non-surgical aesthetics market SEOUL, South Korea, Aug. 11, 2025 /PRNewswire/ -- AMI Pharm, a biotechnology company specializing in next-generation aesthetic solutions, today announced that its lead drug candidate, AYP-101, has entered a pivotal Phase 3 clinical trial for the treatment of submental fat (commonly known as a "double chin"). This innovative injectable drug is designed to dramatically improve patient comfort by utilizing a novel biological mechanism that minimizes the pain and swelling commonly associated with existing treatments. A Paradigm Shift in Fat Reduction Therapy Currently, the only FDA-approved drug for localized fat reduction is based on deoxycholic acid, which destroys fat cells through necrosis —a process that induces inflammation and leads to significant side effects such as pain, bruising, and prolonged swelling. In contrast, AYP-101 is uniquely engineered to eliminate fat through apoptosis, a natural and controlled form of programmed cell death that does not trigger inflammation. This non-cytolytic mechanism offers a gentler, more tolerable alternative, potentially eliminating the need for social downtime and offering a safer, more comfortable experience for patients seeking non-surgical fat reduction. Phase 3 Trial Underway Following Strong Early Results The ongoing Phase 3 clinical trial involves 252 participants across multiple sites in South Korea and is expected to be completed by the end of 2025. The study builds on successful Phase 1 and 2 trials, which met all primary safety and efficacy endpoints. In the Phase 2 trial, over 70% of patients in the AYP-101 group achieved at least a 1-grade improvement on the Evaluator-Reported Submental Fat Rating Scale (ER-SMFRS) in the per-protocol (PP) population. The treatment also showed excellent tolerability and safety, with minimal adverse events reported. "AYP-101 represents the culmination of two decades of dedicated research aimed at creating a safe, effective, and globally competitive solution for localized fat reduction," said Ki-Taek Lee, CEO of AMI Pharm. "By leveraging a novel mechanism of action, we are pioneering the next generation of injectable drugs in aesthetic medicine." Targeting Global Expansion and Broader Indications AMI Pharm is actively preparing for global commercialization. The company is engaging international partners and showcasing its clinical data at world-renowned conferences, including the BIO International Convention and the IMCAS World Congress. While the current clinical focus is on submental fat, AMI Pharm is laying the groundwork to expand AYP-101's indications to address other high-demand aesthetic areas, including cellulite, deep buccal (cheek) fat, and upper arm fat. This broader R&D strategy highlights the company's commitment to addressing a wide spectrum of unmet needs in the aesthetic space and reinforces its ambition to become a global leader in non-surgical body contouring.
Korea Herald
06-08-2025
- Korea Herald
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
INCHEON, South Korea, Aug. 6, 2025 /PRNewswire/ -- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication of the intravenous (IV) formulation of AVTOZMA ® (tocilizumab-anoh) to include the treatment of cytokine release syndrome (CRS) in adults and pediatric patients aged 2 years and older. Following FDA approval of the additional indication for CRS, AVTOZMA IV now aligns with all indications approved for ACTEMRA ® IV in the United States. [1] Earlier this year, the FDA approved AVTOZMA as a biosimilar to ACTEMRA in IV formulations for the treatment of multiple diseases including rheumatoid arthritis (RA), giant cell arteritis (GCA), polyarticular juvenile idiopathic arthritis (pJIA), systemic juvenile idiopathic arthritis (sJIA) and coronavirus disease (COVID-19). [1] CRS is a potentially life-threatening condition that occurs when the immune system is highly activated, leading to the rapid and excessive release of cytokines into the bloodstream. During a cytokine storm, the overactivated immune system can cause widespread inflammation and damage to healthy tissue and organs throughout the body with symptoms ranging from mild, flu-like symptoms to more severe complications such as low blood pressure, difficulty breathing, and multi-organ failure. [2] "We are proud that AVTOZMA IV has now achieved full indication alignment with the reference ACTEMRA IV. This milestone marks an important step forward in our mission to deliver a safe and effective therapy for CRS," said Thomas Nusbickel, Chief Commercial Officer at Celltrion USA. "This FDA approval expands access to high-quality biologics and supports beneficial patient outcomes across multiple therapeutic areas." In accordance with the patent settlement agreement with Genentech, the IV formulation of AVTOZMA is expected to be available in the U.S. on August 31, 2025. Celltrion holds a license to market the subcutaneous formulation in the U.S. commencing on the licensed launch date, which remains confidential. Notes to Editors: AVTOZMA ® (tocilizumab-anoh), containing the active ingredient tocilizumab, is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist. Based on data from the global Phase III clinical trial designed to evaluate the efficacy, pharmacokinetics (PK), safety, and immunogenicity of CT-P47 compared to reference tocilizumab. AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. INDICATION AVTOZMA ® (tocilizumab-anoh) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS INFECTIONS AVTOZMA ® and other tocilizumab products may increase the risk of serious infections, potentially leading to hospitalization or death, especially in patients using concurrent immunosuppressants. If a serious infection develops, interrupt AVTOZMA until the infection is controlled. Reported infections include: Monitor patients for signs of infection, including TB, during and after AVTOZMA treatment. Contraindications: Known hypersensitivity to tocilizumab products. Serious Infections. Serious and sometimes fatal infections have been reported with AVTOZMA. Do not use during active infections, including localized infections. Discontinue AVTOZMA if a serious infection occurs and resume only once controlled. Gastrointestinal (GI) Perforation. Gastrointestinal perforations, often linked to diverticulitis, have been reported with tocilizumab. Use AVTOZMA cautiously in high-risk patients and promptly evaluate new abdominal symptoms for early detection and management. Hepatoxicity. Monitor for hepatic injury signs. Avoid AVTOZMA if ALT/ AST >1.5x ULN (RA/GCA) or >10x ULN (COVID-19); discontinue if ALT/AST >5x ULN or symptoms of liver disease develop. Changes in Laboratory Parameters. Monitor neutrophils, platelets, liver enzymes, and lipids due to potential treatment-related changes; avoid initiating AVTOZMA in patients with critically low ANC or platelet counts. Immunosuppression. The impact of AVTOZMA on malignancy development is unknown, but it may increase risk as an immunosuppressant. Hypersensitivity Reactions, including anaphylaxis, and death, have occurred; administer IV infusions with anaphylaxis management support, discontinue permanently if reactions occur, and avoid use in patients with known hypersensitivity. Demyelinating Disorders. The impact of tocilizumab on demyelinating disorders is unknown, but rare cases were reported; monitor symptoms and use caution with preexisting or recent disorders. Active Hepatic Disease and Hepatic Impairment. Treatment with AVTOZMA is not recommended. Live Vaccines. Avoid concurrent use with AVTOZMA. Adverse Reactions (≥5%) include upper respiratory tract infections, nasopharyngitis, headache, hypertension, elevated ALT, and injection site reactions. About Celltrion Celltrion is a leading biopharmaceutical company based in Incheon, South Korea that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion endeavors to offer high-quality, cost-effective solutions through an extensive global network that spans more than 110 countries. Celltrion has seven biosimilars approved by the U.S. FDA: INFLECTRA ® (infliximab-dyyb), TRUXIMA ® (rituximab-abbs), HERZUMA ® (trastuzumab-pkrb), VEGZELMA ® (bevacizumab-adcd), YUFLYMA ® (adalimumab-aaty), STEQEYMA ® (ustekinumab-stba), and AVTOZMA ® (tocilizumab-anoh), as well as novel biologic ZYMFENTRA ® (infliximab-dyyb). For more information, please visit Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws. This press release contains forward looking statements. These statements may be also identified by words such as "prepares", "hopes to", "upcoming", "plans to", "aims to", "to be launched", "is preparing", "once gained", "could", "with the aim of", "may", "once identified", "will", "working towards", "is due", "become available", "has potential to", "anticipates", the negative of these words or such other variations thereon or comparable terminology. In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion Inc. and its subsidiaries' management, of which many are beyond its control. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company's business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements. Celltrion Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws.
